ATE394673T1 - Selbstanordnende moleküle - Google Patents

Selbstanordnende moleküle

Info

Publication number
ATE394673T1
ATE394673T1 AT02781023T AT02781023T ATE394673T1 AT E394673 T1 ATE394673 T1 AT E394673T1 AT 02781023 T AT02781023 T AT 02781023T AT 02781023 T AT02781023 T AT 02781023T AT E394673 T1 ATE394673 T1 AT E394673T1
Authority
AT
Austria
Prior art keywords
self
assembly
target
molecules
single domain
Prior art date
Application number
AT02781023T
Other languages
English (en)
Inventor
C Mackenzie
Jianbing Zhang
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Application granted granted Critical
Publication of ATE394673T1 publication Critical patent/ATE394673T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Electroluminescent Light Sources (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
AT02781023T 2001-11-30 2002-11-29 Selbstanordnende moleküle ATE394673T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33409801P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
ATE394673T1 true ATE394673T1 (de) 2008-05-15

Family

ID=23305560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02781023T ATE394673T1 (de) 2001-11-30 2002-11-29 Selbstanordnende moleküle

Country Status (14)

Country Link
US (1) US7655412B2 (de)
EP (1) EP1456651B1 (de)
JP (1) JP4471656B2 (de)
CN (1) CN100335900C (de)
AT (1) ATE394673T1 (de)
AU (1) AU2002349228B2 (de)
BR (1) BR0214621A (de)
CA (1) CA2468583C (de)
DE (1) DE60226486D1 (de)
DK (1) DK1456651T3 (de)
ES (1) ES2306794T3 (de)
MX (1) MXPA04005134A (de)
NZ (1) NZ532838A (de)
WO (1) WO2003046560A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
EP2711025A3 (de) * 2003-06-25 2014-09-10 Massachusetts Institute of Technology Selbstangeordnete Peptide mit Modifikationen und Verwendungsverfahren dafür
US7713923B2 (en) 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
DE602004017726D1 (de) * 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
EP1694845B8 (de) * 2003-11-28 2017-12-20 National Research Council of Canada Antikarzinom-antikörper und verwendungen davon
EP1737971B1 (de) * 2004-01-20 2017-08-16 Merus N.V. Gemische bindender proteine
WO2007036022A1 (en) * 2005-09-27 2007-04-05 National Research Council Of Canada Targeted delivery of compounds using multimerization technology
EP2121726A4 (de) * 2006-12-04 2010-10-20 Innovative Purification Techno Proteinpartikel
CA2688557A1 (en) * 2007-05-30 2008-12-04 Innovative Purification Technologies Pty Ltd Fluorescent protein particles
CA2740716A1 (en) * 2008-10-14 2010-04-22 Dow Agrosciences Llc Induction of mucosal immune responses by mucosal delivery pentabody complex (mdpc)
EP2692736B1 (de) 2008-10-14 2018-04-18 National Research Council Of Canada Bsa-spezifische antikörper
US20110269148A1 (en) * 2008-11-26 2011-11-03 National Cheng Chung University Nanoaggregate Embedded Beads Conjugated To Single Domain Antibodies
WO2010102518A1 (zh) * 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
CN101830986A (zh) * 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
US20100247529A1 (en) * 2009-03-20 2010-09-30 William Patterson Cooperative and dynamic assembly of affinity complexes
EP2563816B1 (de) 2010-04-27 2014-11-12 National Research Council of Canada Einzeldomänen-antikörper gegen icam 1 und verwendung davon
PL2621955T3 (pl) 2010-10-01 2018-07-31 National Research Council Of Canada Przeciwciała anty-CEACAM6 i ich zastosowania
EP2632949B1 (de) 2010-10-25 2017-09-13 National Research Council of Canada Clostridium-difficile-spezifische antikörper und verwendungen davon
JP6093715B2 (ja) 2011-01-28 2017-03-08 ナショナル リサーチ カウンシル オブ カナダ 免疫グロブリンドメインの工学的作製
ES2785349T3 (es) 2011-06-10 2020-10-06 Canada Minister Nat Defence Anticuerpos anti-ricina y sus usos
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN104870472A (zh) 2012-10-24 2015-08-26 加拿大国家研究委员会 抗空肠弯曲杆菌抗体及其用途
PE20170088A1 (es) 2014-03-06 2017-03-09 Nat Res Council Canada Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
NZ724869A (en) 2014-03-06 2022-07-01 Nat Res Council Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
DK3114141T3 (da) 2014-03-06 2020-08-10 Nat Res Council Canada Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf
CN104004093B (zh) * 2014-06-03 2017-01-18 大连理工大学 一种抗人甲状旁腺激素的纳米抗体及其筛选方法和应用
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
CA3001724A1 (en) 2014-10-10 2016-04-14 National Research Council Of Canada Anti-tau antibody and uses thereof
EP4019552A1 (de) 2015-06-10 2022-06-29 National Research Council of Canada Carboanhydrase-ix-spezifische antikörper und verwendungen davon
BR112019000220A2 (pt) 2016-07-06 2019-04-24 National Research Council Of Canada anticorpos humanizados que transmigram a barreira hematoencefálica e usos dos mesmos
WO2018109663A1 (en) 2016-12-12 2018-06-21 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
CA3051377A1 (en) 2017-01-27 2018-08-02 National Research Council Of Canada Hemagglutinin-specific antibodies and uses thereof
WO2018138709A1 (en) 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
US12344671B2 (en) 2018-04-24 2025-07-01 National Research Council Of Canada Blood-brain barrier transmigrating therapeutic compounds and uses thereof
US12240916B2 (en) 2018-09-21 2025-03-04 National Research Council Of Canada Intrabodies for reducing FUT8 activity
WO2020086793A1 (en) * 2018-10-25 2020-04-30 Hao Shen Self-assembling protein homo-polymers
EP3947469A4 (de) 2019-04-02 2022-12-14 National Research Council of Canada Antikörpervarianten mit ph-abhängiger antigenbindung für selektives targeting von soliden tumoren
CN114099701B (zh) * 2021-11-29 2023-11-10 华中科技大学同济医学院附属协和医院 一种自组装复合多肽及其制备方法和药物
CA3248183A1 (en) 2022-04-14 2023-10-19 The Hospital For Sick Children PFCSP-BASED IMMUNOGENS AND ASSOCIATED COMPOSITION AND METHODS
CN116478303A (zh) * 2023-04-27 2023-07-25 中国人民解放军军事科学院军事医学研究院 可自组装为纳米颗粒的融合蛋白及其在免疫中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5955293A (en) * 1989-10-17 1999-09-21 New England Medical Center Hospitals, Inc. Assays for shiga toxin and shiga-like toxins
ES2156149T3 (es) * 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
EP0923738A1 (de) * 1996-06-11 1999-06-23 Advanced Research & Technology Institute Verfahren und zubereitungen für die verwendung von apurinischen/apyrimidinischen endonukleasen
DE69738670D1 (de) * 1996-10-28 2008-06-19 Inst Suisse De Rech S Experime Verfahren zur oligomerisation von peptiden
HUP0002760A3 (en) * 1997-05-12 2003-03-28 Aphton Corp Woodland Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
DE69829995T2 (de) * 1997-12-01 2006-02-23 Fang, Fang, San Diego Multivalente rekombinante antikörper zur behandlung von hrv infektionen
US6310043B1 (en) * 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
MXPA01007602A (es) * 1999-02-01 2003-06-24 Beth Israel Hospital Comp/tsp-1, comp/tsp-2 y otras proteinas quimericas..
WO2000061183A2 (en) * 1999-04-09 2000-10-19 Hsc Research And Development Limited Partnership Verotoxin treatment of lymphomas
CA2385172A1 (en) 1999-10-08 2001-04-19 Active Biotech Ab Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
AU2001227966A1 (en) * 2000-01-20 2001-07-31 Chiron Corporation Methods for treating tumors

Also Published As

Publication number Publication date
AU2002349228A1 (en) 2003-06-10
US7655412B2 (en) 2010-02-02
WO2003046560B1 (en) 2003-10-16
CA2468583A1 (en) 2003-06-05
NZ532838A (en) 2008-05-30
AU2002349228B2 (en) 2007-06-14
JP2005510719A (ja) 2005-04-21
CA2468583C (en) 2012-05-01
WO2003046560A2 (en) 2003-06-05
MXPA04005134A (es) 2004-08-11
CN100335900C (zh) 2007-09-05
BR0214621A (pt) 2004-10-13
EP1456651A2 (de) 2004-09-15
ES2306794T3 (es) 2008-11-16
JP4471656B2 (ja) 2010-06-02
EP1456651B1 (de) 2008-05-07
WO2003046560A3 (en) 2003-09-04
DK1456651T3 (da) 2008-09-01
CN1596371A (zh) 2005-03-16
US20060051292A1 (en) 2006-03-09
DE60226486D1 (de) 2008-06-19

Similar Documents

Publication Publication Date Title
DK1456651T3 (da) Selvsamlende molekyler
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
EA201100527A1 (ru) Биологические продукты
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
DE602006013029D1 (de) Anti-egfr-antikörper
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA200800812A1 (ru) Композиции антитела против cd3
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MA43028B1 (fr) Anticorps bispécifiques pour pd1 et tim3
CY1118949T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
PT1639011E (pt) Anticorpos (dab) de domínio único peguilados
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
PT1766093E (pt) Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
CR9471A (es) Anticuerpos de p-caderina
AU9399501A (en) Therapeutic antibodies
NZ598770A (en) Monoclonal antibodies
PT1190257E (pt) Deteccao precoce dos flavivirus, utilizando a glicoproteina ns1
NO20021686D0 (no) Fremgangsmåter for fremstilling av målemolekyler i et transgent dyr og rensing av målmolekylet
AU2002357779A1 (en) Identification of high affinity molecules by limited dilution screening

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1456651

Country of ref document: EP